Evidence map›Paper›PMID 38284716›Full record

ArticleCurrent protein & peptide science2024

Heparin Oligosaccharides as Vasoactive Intestinal Peptide Inhibitors via their Binding Process Characterization.

Meixin Li, Yaqi Xue, Lianli Chi, Lan Jin

Abstract read
PubMed Publisher
In one paragraph

Article in Current protein & peptide science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Meixin LiNational Glycoengineering Research Center, NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate- based Medicine, Shandong University, Qingdao, Shandong, 266237, China.
Yaqi XueNational Glycoengineering Research Center, NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate- based Medicine, Shandong University, Qingdao, Shandong, 266237, China.
Lianli ChiNational Glycoengineering Research Center, NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate- based Medicine, Shandong University, Qingdao, Shandong, 266237, China.
Lan JinNational Glycoengineering Research Center, NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate- based Medicine, Shandong University, Qingdao, Shandong, 266237, China.

Funding

National Key R&D Program of China 2021YFC2103100
6 · The paper itself

Abstract

backgroundIt has been proven that vasoactive intestinal peptide (VIP) was involved in the pathogenesis of prostate cancer. Cardin

objectiveA variety of experiments were designed to study the binding process and structure-activity relationship between heparin oligosaccharides and VIP.

methodsHeparin was enzymatically digested and purified to produce heparin oligosaccharides, and the structures were characterized by NMR. The binding capacity between heparin oligosaccharides and VIP was analyzed by GMSA and ITC experiments. The binding between heparin oligosaccharides and VIP was simulated using a molecular docking program to show the complex. ELISA assay was used to investigate the effect of non-anticoagulant heparin oligosaccharides on the VIP-mediated cAMP/PKA signaling pathway

resultsThe results indicated that both the length and the sulfation pattern of heparin oligosaccharides affected its binding to VIP. VIP could induce the expression of cAMP at a higher level in PC3 cells, which could be regulated by the interaction of heparin oligosaccharides and VIP.

conclusionThe binding between heparin oligosaccharides and VIP could block the binding between VIP and its receptor on tumor cells. Downloading the regulation of the expression level of cAMP could possibly further affect the subsequent activation of PKA. These non-anticoagulant heparin oligosaccharides may block the VIP-mediated cAMP/PKA signaling pathway and thus exert their antitumor activity.

Indexed as

Cyclic AMPCyclic AMP-Dependent Protein KinasesHeparinMolecular Docking SimulationOligosaccharidesProtein BindingSignal TransductionVasoactive Intestinal PeptideBinding SitesCell Line, TumorHumansMaleProstatic NeoplasmsStructure-Activity RelationshipCyclic AMPCyclic AMP-Dependent Protein KinasesHeparinOligosaccharidesVasoactive Intestinal PeptidecAMP.ELISA assayHeparin oligosaccharidesinteractionisothermal titration calorimetryvasoactive intestinal peptide

Identifiers

PMID38284716

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.